Where to buy Tisotumab vedotin-tftv

Tisotumab vedotin-tftv, trade nameTivdak, is an antibody-drug conjugate (ADC) for the treatment of cervical cancer. It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. It is administered intravenously. Vitin-Tisotuzumab was approved for medical use in the United States in September 2021, and the U.S. Food and Drug Administration (FDA) considered it a first-in-class drug.

Nonclinical data suggest that the anticancer activity of Vitin-tisotuzumab is due to ADC binding to TF-expressing cancer cells, subsequent internalization of the ADC-TF complex, and release of MMAE through proteolytic cleavage. MMAE disrupts the microtubule network of actively dividing cells, leading to cell cycle arrest and apoptotic cell death. In vitro, Vitin-Tisotuzumab also mediates antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity. After dosing a 3-week cycle of Vitin-Tesotuzumab 2 mg/kg, peak concentrations were reached near the end of the infusion, while unbound MMAE concentrations peaked approximately 2 to 3 days after Vertin-Tesotuzumab administration.

Vitin-TisotuzumabThe original drug has not yet been launched in China, so it cannot be included in medical insurance. Domestic patients cannot yet purchase this drug. The original drugs marketed overseas are very expensive. The price of each box of 40 mg/vial may be around RMB 90,000 (the price may fluctuate due to the exchange rate). Currently, there is no generic version of Vitin-Tisotuzumab on the market. For more drug information and specific prices, please consult the medical consultant of the drug.